AstraZeneca aims to widen the pool of bladder cancer patients who can be treated with its PD-L1 inhibitor Imfinzi after the ...

Join leading experts to discuss how we are ushering in a new era in bladder cancer care on May 28 virtually. Register now.

The Food and Drug Administration (FDA) has approved Imfinzi ® (durvalumab), in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent Imfinzi as adjuvant ...

UroGen Pharma ( NASDAQ: URGN) announced on Wednesday that the U.S. FDA has scheduled an Oncologic Drugs Advisory Committee ...

Compared with other common malignancies, bladder cancer has been relatively understudied ... devoted to this topic at the ...

Updated findings from a phase 2 study investigating the IL-2–binding monoclonal antibody AU-007 show a manageable safety ...

AUA annual meeting featured the IBCG Bladder Cancer Forum evaluating common problems and controversies in bladder cancer, moderated by Dr. Laura Mertens, with a debate between Drs. Joshua Meeks and ...

The positive predictive value (PPV) for Bladder EpiCheck was 67.4%, with a negative predictive value (NPV) for both overall and HG disease of 99.6%. WLC demonstrated a PPV of 74%, an NPV of 96.3%, and ...

Terry Bradshaw was the golden-armed leader of the Pittsburgh Steelers dynasty, a two-time Super Bowl MVP, a four-time ...

Why Chicago's life-sciences incubator is expanding its footprint again How NIH funding cuts could impact Chicago How NIH funding cuts could impact Chicago 12 Chicago startups to watch in 2025 12 ...

3 "Patients with bladder cancer need more effective treatment options that are both tolerable and easily incorporated into everyday practice, especially for those with HR-NMIBC, a highly recurrent ...

Before the Trodelvy readout, a combination of Pfizer and Astellas’ Nectin-4 ADC Padcev and Keytruda won a full FDA approval in late 2023 as a first-line treatment for advanced bladder cancer.